Elanco Animal Health Incorporated
ELAN
Rang in Aktien
#1873
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces,... Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.
Aktienkurs
$22.70
Zuletzt synchronisiert: 2026-10-20
Marktkapitalisierung
$11.34B
Veränderung (1 Tag)
-3.45%
Veränderung (1 Jahr)
4.97%
Land
US
Handel Elanco Animal Health Incorporated (ELAN)
Kategorie
Healthcare
Umsatz von Elanco Animal Health Incorporated (ELAN)
Umsatz im Jun 2026 TTM: $5.02B
Laut den aktuellen Finanzberichten von Elanco Animal Health Incorporated beträgt der derzeitige Umsatz des Unternehmens (TTM) $5.02B. Im Jahr 2023 erzielte das Unternehmen einen Umsatz von $4.42B eine Steigerung gegenüber dem Umsatz im Jahr 2022, der $4.41B betrug. Der Umsatz ist der Gesamtbetrag, den ein Unternehmen durch den Verkauf von Waren oder Dienstleistungen erzielt. Im Gegensatz zum Gewinn werden keine Ausgaben abgezogen.
Umsatzverlauf für Elanco Animal Health Incorporated von 2015 bis 2026
Umsatz am Ende jedes Jahres
| Jahr | Umsatz | ändert |
|---|---|---|
| 2026 (TTM) | $5.02B | 13.09% |
| 2024 | $4.44B | 0.50% |
| 2023 | $4.42B | 0.14% |
| 2022 | $4.41B | -7.41% |
| 2021 | $4.76B | 45.54% |
| 2020 | $3.27B | 6.59% |
| 2019 | $3.07B | 0.14% |
| 2018 | $3.07B | 6.15% |
| 2017 | $2.89B | -0.84% |
| 2016 | $2.91B | 0.15% |
| 2015 | $2.91B | 0.00% |
Umsatz vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Umsatz | Umsatzunterschied | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 31.71% |
IN
|
